Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 19;45(4):236-242.
doi: 10.1136/bmjsrh-2019-200395. Online ahead of print.

Male contraception: where are we going and where have we been?

John Joseph Reynolds-Wright  1 , Richard Anderson  2
Affiliations
Review

Male contraception: where are we going and where have we been?

John Joseph Reynolds-Wright et al. BMJ Sex Reprod Health. .

Erratum in

Abstract

Progress in developing new reversible male contraception has been slow. While the hormonal approach has been clearly shown to be capable of providing effective and reversible contraception, there remains no product available. Currently, trials of a self-administered gel combination of testosterone and the progestogen Nestorone® are under way, complementing the largely injectable methods previously investigated. Novel long-acting steroids with both androgenic and progestogenic activity are also in early clinical trials. The non-hormonal approach offers potential advantages, with potential sites of action on spermatogenesis, and sperm maturation in the epididymis or at the vas, but remains in preclinical testing. Surveys indicate the willingness of men, and their partners, to use a new male method, but they continue to lack that opportunity.

Keywords: hormonal contraception; male contraception; review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
The hypothalamic-pituitary-testicular axis and its role in spermatogenesis. CCBY 4.0 Licence – John Reynolds-Wright. Image accessible via https://flic.kr/p/2hgvk5V6A. FSH, follicle stimulating hormone; GnRH, gonadotrophin-releasing hormone; LH, luteinising hormone.
See this image and copyright information in PMC

References

    1. Faculty of Sexual and Reproductive Healthcare Better care, a better future: a new vision for sexual and reproductive health care in the UK, 2015. Available: https://www.fsrh.org/documents/fsrh-vision/
    1. Coviello AD, Bremner WJ, Matsumoto AM, et al. . Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 2004;25:931–8. 10.1002/j.1939-4640.2004.tb03164.x - DOI - PubMed
    1. Waites GMH. Development of methods of male contraception: impact of the world Health organization Task force. Fertil Steril 2003;80:1–15. 10.1016/S0015-0282(03)00577-6 - DOI - PubMed
    1. World Health Organization Task Force on Methods for the Regulation of Male Fertility Contraceptive efficacy of testosterone-induced azoospermia in normal men. The Lancet 1990;336:955–9. 10.1016/0140-6736(90)92416-F - DOI - PubMed
    1. World Health Organization Task Force on Methods for the Regulation of Male Fertility Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996;65:821–9. 10.1016/S0015-0282(16)58221-1 - DOI - PubMed

LinkOut - more resources